EFFICACY AND SAFETY OF ETOPOSIDE IN COMBINATION WITH G-CSF, LOW-DOSE CYTARABINE AND ACLARUBICIN IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. ZHANG C. 06/09/16; 135356; LB2245
Prof. Cheng ZHANG
Contributions
Contributions
Abstract
Abstract: LB2245
Type: Eposter Presentation
Background
Chemotherapy for elderly patients with acute myeloid leukemia (AML) is still a great challenge. Although 50% AML patients could achieve complete remission (CR) after intensive 3+7 regimen, treatment-related toxicities (TRT) appeared particularly prominent in elderly patients. In 2013, a multi-center randomized controlled trial in southwestern China confirmed that 71.1% refractory or relapsed AML achieved CR after received etoposide combine with low-dose CAG (E-CAG) regimen, and TRT was low, with no mortality.
Aims
This prospective phase II, open label, randomized controlled study was designed to assess the efficacy and safety of E-CAG induction treatment for elderly patients with newly diagnosed AML.
Methods
The effect of E-CAG on the rate of CR was the main study end-point. The median survival time and the toxicity of the E-CAG regimen were also evaluated.
Results
After induction chemotherapy, patients with E-CAG regimen had a similar CR rate than did patients who received DA regimen (55.1% vs. 48.9%, P=0.158). The tolerability profiles of E-CAG regimen appeared better than DA regimen. Especially, gastrointestinal reaction and III-IV bone marrow suppression. The median survival time was extended for 4 months in E-CAG group (14.3 months vs. 10.3 months, P=0.042). The two-year OS probability in E-CAG group and DA group was 24.2% and 11.3%, perspectively.
Conclusion
The E-CAG regimen seems promising and offers lower toxicity for the treatment of elderly patients with AML, and expected to become a bridge for non-myeloablative stem cell transplantation.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, G-CSF
Type: Eposter Presentation
Background
Chemotherapy for elderly patients with acute myeloid leukemia (AML) is still a great challenge. Although 50% AML patients could achieve complete remission (CR) after intensive 3+7 regimen, treatment-related toxicities (TRT) appeared particularly prominent in elderly patients. In 2013, a multi-center randomized controlled trial in southwestern China confirmed that 71.1% refractory or relapsed AML achieved CR after received etoposide combine with low-dose CAG (E-CAG) regimen, and TRT was low, with no mortality.
Aims
This prospective phase II, open label, randomized controlled study was designed to assess the efficacy and safety of E-CAG induction treatment for elderly patients with newly diagnosed AML.
Methods
The effect of E-CAG on the rate of CR was the main study end-point. The median survival time and the toxicity of the E-CAG regimen were also evaluated.
Results
After induction chemotherapy, patients with E-CAG regimen had a similar CR rate than did patients who received DA regimen (55.1% vs. 48.9%, P=0.158). The tolerability profiles of E-CAG regimen appeared better than DA regimen. Especially, gastrointestinal reaction and III-IV bone marrow suppression. The median survival time was extended for 4 months in E-CAG group (14.3 months vs. 10.3 months, P=0.042). The two-year OS probability in E-CAG group and DA group was 24.2% and 11.3%, perspectively.
Conclusion
The E-CAG regimen seems promising and offers lower toxicity for the treatment of elderly patients with AML, and expected to become a bridge for non-myeloablative stem cell transplantation.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, G-CSF
Abstract: LB2245
Type: Eposter Presentation
Background
Chemotherapy for elderly patients with acute myeloid leukemia (AML) is still a great challenge. Although 50% AML patients could achieve complete remission (CR) after intensive 3+7 regimen, treatment-related toxicities (TRT) appeared particularly prominent in elderly patients. In 2013, a multi-center randomized controlled trial in southwestern China confirmed that 71.1% refractory or relapsed AML achieved CR after received etoposide combine with low-dose CAG (E-CAG) regimen, and TRT was low, with no mortality.
Aims
This prospective phase II, open label, randomized controlled study was designed to assess the efficacy and safety of E-CAG induction treatment for elderly patients with newly diagnosed AML.
Methods
The effect of E-CAG on the rate of CR was the main study end-point. The median survival time and the toxicity of the E-CAG regimen were also evaluated.
Results
After induction chemotherapy, patients with E-CAG regimen had a similar CR rate than did patients who received DA regimen (55.1% vs. 48.9%, P=0.158). The tolerability profiles of E-CAG regimen appeared better than DA regimen. Especially, gastrointestinal reaction and III-IV bone marrow suppression. The median survival time was extended for 4 months in E-CAG group (14.3 months vs. 10.3 months, P=0.042). The two-year OS probability in E-CAG group and DA group was 24.2% and 11.3%, perspectively.
Conclusion
The E-CAG regimen seems promising and offers lower toxicity for the treatment of elderly patients with AML, and expected to become a bridge for non-myeloablative stem cell transplantation.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, G-CSF
Type: Eposter Presentation
Background
Chemotherapy for elderly patients with acute myeloid leukemia (AML) is still a great challenge. Although 50% AML patients could achieve complete remission (CR) after intensive 3+7 regimen, treatment-related toxicities (TRT) appeared particularly prominent in elderly patients. In 2013, a multi-center randomized controlled trial in southwestern China confirmed that 71.1% refractory or relapsed AML achieved CR after received etoposide combine with low-dose CAG (E-CAG) regimen, and TRT was low, with no mortality.
Aims
This prospective phase II, open label, randomized controlled study was designed to assess the efficacy and safety of E-CAG induction treatment for elderly patients with newly diagnosed AML.
Methods
The effect of E-CAG on the rate of CR was the main study end-point. The median survival time and the toxicity of the E-CAG regimen were also evaluated.
Results
After induction chemotherapy, patients with E-CAG regimen had a similar CR rate than did patients who received DA regimen (55.1% vs. 48.9%, P=0.158). The tolerability profiles of E-CAG regimen appeared better than DA regimen. Especially, gastrointestinal reaction and III-IV bone marrow suppression. The median survival time was extended for 4 months in E-CAG group (14.3 months vs. 10.3 months, P=0.042). The two-year OS probability in E-CAG group and DA group was 24.2% and 11.3%, perspectively.
Conclusion
The E-CAG regimen seems promising and offers lower toxicity for the treatment of elderly patients with AML, and expected to become a bridge for non-myeloablative stem cell transplantation.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, G-CSF
{{ help_message }}
{{filter}}